Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Physiology. Heart and Circulatory Physiology

• Publication date

  2007-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/AJPHEART.01174.2006PMID 17322416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside.

  2006cited by this paper
• Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines

  2006cited by this paper
• Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts.

  2005cited by this paper
• Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice: Inhibitory Effect on Monocyte Chemotaxis

  2005cited by this paper
• Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice.

  2005cited by this paper
• Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice.

  2005cited by this paper
• Cardiovascular risk profile in patients treated with sirolimus after renal transplantation.

  2005cited by this paper
• The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation.

  2004cited by this paper
• Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway.

  2004influential reference
• Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin.

  2004cited by this paper
• PPAR Agonists Protect Mesangial Cells from Interleukin 1β-Induced Intracellular Lipid Accumulation by Activating the ABCA1 Cholesterol Efflux Pathway

  2003cited by this paper
• Results of renal transplantation over 20 years after surgery, using azathioprine and low-dose prednisolone as the sole immunosuppression.

  2003cited by this paper
• Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading

  2003cited by this paper
• Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.

  2003cited by this paper
• Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice.

  2003cited by this paper
• Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

  2003cited by this paper
• PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway.

  2003cited by this paper
• Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E‐Deficient Mice

  2003influential reference
• Inflammation modifies lipid-mediated renal injury.

  2003cited by this paper
• Dysregulation of LDL receptor by an inflammatory cytokine: A new pathway for foam cell formation in vascular smooth muscle cells.

  2003cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Inflammation and immune responses in atherosclerosis.

  2002cited by this paper
• Drug-eluting stents in the treatment of atherosclerotic coronary heart disease.

  2002cited by this paper
• Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200

  2002cited by this paper
• Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.

  2002cited by this paper
• Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation.

  2002cited by this paper
• Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.

  2001cited by this paper
• ADJUNCTIVE RAPAMYCIN AND CsA TREATMENT INHIBITS MONOCYTE/MACROPHAGE ASSOCIATED CYTOKINES/CHEMOKINES IN SENSITIZED CARDIAC GRAFT RECIPIENTS1

  2001cited by this paper
• Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation.

  2001cited by this paper
• Molecular link between cholesterol, cytokines and atherosclerosis

  2001cited by this paper
• Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study

  2001cited by this paper
• Interleukin-1β causes different levels of nitric oxide-mediated depression of contractility in different positions of rat thoracic aorta

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

  1999cited by this paper
• Human mesangial cells express inducible macrophage scavenger receptor.

  1999cited by this paper
• Interleukin-1beta causes different levels of nitric oxide-mediated depression of contractility in different positions of rat thoracic aorta.

  1999cited by this paper
• Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis

  1998cited by this paper
• The combined role of P- and E-selectins in atherosclerosis.

  1998cited by this paper
• Rapamycin inhibits vascular smooth muscle cell migration.

  1996cited by this paper
• Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease

  1996cited by this paper
• Interleukin-1 beta in coronary arteries of patients with ischemic heart disease.

  1996cited by this paper
• Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E.

  1995cited by this paper
• Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells.

  1995cited by this paper
• Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels.

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis.

  1991cited by this paper
• Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits.

  1990cited by this paper
• Development of the smooth muscle foam cell: uptake of macrophage lipid inclusions.

  1986cited by this paper
• Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery

  1985cited by this paper
• Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells.

  1978cited by this paper

• Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential

  2025cites this paper
• Investigating the potential anti-depressive mechanisms of statins: a transcriptomic and Mendelian randomization analysis

  2023cites this paper
• Cardiovascular effects of immunosuppression agents

  2022cites this paper
• mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer

  2022cites this paper
• New insight into dyslipidemia‐induced cellular senescence in atherosclerosis

  2022cites this paper
• Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients

  2021cites this paper
• Lipid accumulation and novel insight into vascular smooth muscle cells in atherosclerosis

  2021cites this paper
• The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside

  2021cites this paper
• Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus.

  2020cites this paper
• Rapamycin inhibits peritoneal fibrosis by modifying lipid homeostasis in the peritoneum.

  2019cites this paper
• Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

  2019cites this paper
• Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment

  2019cites this paper
• Publisher Correction: Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy

  2019cites this paper
• LncRNA ENST00000602558.1 regulates ABCG1 expression and cholesterol efflux from vascular smooth muscle cells through a p65-dependent pathway.

  2019cites this paper
• Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

  2018cites this paper
• Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients

  2017cites this paper
• AMP-activated protein kinase α1 promotes atherogenesis by increasing monocyte-to-macrophage differentiation

  2017cites this paper
• mTOR signaling promotes foam cell formation and inhibits foam cell egress through suppressing the SIRT1 signaling pathway

  2017cites this paper
• Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.

  2016cites this paper
• Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway

  2016cites this paper
• Systems biological understanding of the regulatory network and the possible therapeutic strategies for vascular calcification.

  2016cites this paper
• Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease

  2016cites this paper
• Synthesis of three-arm block copolymer poly(lactic-co-glycolic acid)–poly(ethylene glycol) with oxalyl chloride and its application in hydrophobic drug delivery

  2016cites this paper
• Antidepressant indatraline induces autophagy and inhibits restenosis via suppression of mTOR/S6 kinase signaling pathway

  2016cites this paper
• Is It Time to Use De Novo mTOR Inhibitors Posttransplant?

  2016cites this paper
• The Role of mTOR Inhibitors in Solid Organ Transplantation

  2016cites this paper
• mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems.

  2015cites this paper
• Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease.

  2015cites this paper
• Inflammatory stress induces lipid accumulation in multi-organs of db/db mice.

  2015cites this paper
• Autophagy in Vascular Disease

  2015cites this paper
• Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo

  2015cites this paper
• mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?

  2015cites this paper
• Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy

  2015cites this paper
• Rapamune Does Not Attenuate High Cholesterol-Induced Atherosclerosis in Rabbits

  2014cites this paper
• Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis.

  2014cites this paper
• ElEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus

  2014cites this paper
• mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.

  2014cites this paper
• Activation of mTOR contributes to foam cell formation in the radial arteries of patients with end-stage renal disease.

  2014cites this paper
• In‐stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus‐eluting stent to treat a long de novo coronary lesion with small distal vessel diameter

  2013cites this paper
• Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice.

  2013cites this paper
• Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation.

  2013influential citation
• Inflammatory Stress Exacerbates the Progression of Cardiac Fibrosis in High-Fat-Fed Apolipoprotein E Knockout Mice via Endothelial-Mesenchymal Transition

  2013cites this paper
• Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding.

  2013cites this paper
• Enhanced SCAP Glycosylation by Inflammation Induces Macrophage Foam Cell Formation

  2013cites this paper
• Sirolimus and Cardiovascular Disease Risk in Liver Transplantation

  2013cites this paper
• Cholesterol Esterification as a Mediator of Proliferation of Vascular Smooth Muscle Cells and Peripheral Blood Mononuclear Cells during Atherogenesis

  2013cites this paper
• Increased mTORC1 activity contributes to atherosclerosis in apolipoprotein E knockout mice and in vascular smooth muscle cells☆

  2013cites this paper
• Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

  2013cites this paper
• Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

  2012cites this paper
• Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.

  2012cites this paper
• The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats

  2012cites this paper
• Downstream effects of coronary drug-eluting stents: promising prophecy or incidental surveillance?

  2012cites this paper
• Drug-induced macrophage autophagy in atherosclerosis: for better or worse?

  2012influential citation
• Everolimus Triggers Cytokine Release by Macrophages: Rationale for Stents Eluting Everolimus and a Glucocorticoid

  2012cites this paper
• Inflammation Disrupts the LDL Receptor Pathway and Accelerates the Progression of Vascular Calcification in ESRD Patients

  2012cites this paper
• Preclinical Evaluation Methods for Screening of Anti-Atherosclerotic Drugs: An Overview

  2011cites this paper
• Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro.

  2011cites this paper
• Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.

  2011cites this paper
• Calcineurin inhibitor sparing regimens using m‐target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?

  2011cites this paper
• Downstream coronary effects of drug-eluting stents.

  2011cites this paper
• Porphyromonas gingivalis lipopolysaccharide alters atherosclerotic-related gene expression in oxidized low-density-lipoprotein-induced macrophages and foam cells.

  2011cites this paper
• Rapamycin verhindert das Wachstum kolorektaler Metastasen nach Leberesektion durch Hemmung der Angiogenese und Tumorzellproliferation

  2010cites this paper
• Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells.

  2010influential citation
• ATP-Binding Membrane Cassette Transporter A1 (ABCA1): A Possible Link between Inflammation and Reverse Cholesterol Transport

  2010cites this paper
• ABCA 1 : A Possible Link Between Inflammation And Reverse Cholesterol Transport

  2010cites this paper
• Immunosuppressive and antiproteolytic therapy in vascular diseases

  2010cites this paper
• Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor

  2009cites this paper
• Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice.

  2009cites this paper
• Everolimus, a promising medical therapy for coronary heart disease?

  2009cites this paper
• Validation of anti-aging drugs by treating age-related diseases

  2009cites this paper
• Diurnal variation of the human adipose transcriptome and the link to metabolic disease

  2009cites this paper
• The pharmacodynamic effect of sirolimus: individual variation of cytokine mRNA expression profiles in human whole blood samples.

  2009cites this paper
• The antichlamydial effects of drugs used in cardiovascular diseases

  2009cites this paper
• Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

  2008cites this paper
• Cytokines and coronary artery disease: the state of the art.

  2008cites this paper
• Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice

  2008cites this paper
• Bibliography. Current world literature. Atherosclerosis: cell biology and lipoproteins.

  2008cites this paper
• Improved outcome with immunosuppressive monotherapy after renal transplantation in Schimke‐immuno‐osseous dysplasia

  2008cites this paper
• Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice

  2008cites this paper